[시장보고서]세계의 나노의학 시장 : 양식, 용도, 적응증, 분자 유형, 지역별 예측(-2032년)

세계의 나노의학 시장 : 양식, 용도, 적응증, 분자 유형, 지역별 예측(-2032년)

Global Nanomedicine Market Research Report: Information by Modality, by Application, and by Indication, by Molecule Type, and by Region Forecast till 2032

상품코드 : 1607745 해당 상품은 즉시 배송 가능합니다

리서치사 : Market Research Future

발행일 : 2024년 11월

페이지 정보 : 영문 149 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,146,000

PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 5,950

￦ 8,590,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다.

US $ 7,250

￦ 10,467,000

PDF & Excel (Enterprise License)

PDF, Excel 보고서를 동일 기업이 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능하며, 인쇄 가능합니다.

한글목차

샘플 요청 목록에 추가

세계 나노의학 시장 규모는 2023년 2,529억 7,000만 달러, 2024년 2,737억 9,000만 달러에서 예측 기간 동안 12.48%의 CAGR로 2032년에는 8,198억 4,000만 달러 규모로 성장할 것으로 예상됩니다.

이 시장은 전 세계적으로 다양한 질병의 발생이 증가하고 있으며, 나노의학 제품 개발과 관련된 다양한 합의에 의해 주도되고 있습니다.

지역별로는 북미 시장이 암 환자 유병률 증가와 강력한 R&D 인프라로 인해 2023년 38.14% 이상의 시장 점유율을 차지하며 가장 큰 시장 점유율을 기록했습니다. 미국에서는 2020년에 160만 3,844명의 신규 암환자와 60만 2,347명의 암 사망자가 보고되었습니다. 인구 10만 명당 403명의 신규 암 환자가 보고되었고, 144명이 암으로 사망했습니다.

유럽 시장은 나노기술의 발전과 의료 개선 가능성으로 인해 빠르게 성장하고 있습니다. 이 시장은 모니터링, 치료 및 진단을 위한 나노 스케일 재료 및 기술의 개발 및 적용에 전념하고 있으며, 맞춤형 치료에 대한 수요 증가와 만성질환의 유병률 증가로 인해 시장이 발전하고 있습니다. 유럽은 높은 R&D 비용과 우수한 의료 인프라로 인해 나노 의료 혁신의 최전선에 서 있습니다. 표적 약물전달 시스템, 더 나은 암 치료, 나노 스케일 이미징 도구 등이 중점 분야입니다.

아시아태평양도 첨단 헬스케어 기술에 대한 관심과 투자가 증가함에 따라 빠르게 성장하고 있습니다. 헬스케어 수요 증가, 만성질환의 유행, 나노기술 연구의 눈부신 발전 등 여러 요인으로 인해 이 시장은 앞으로도 급성장할 것으로 예상됩니다.

세계 나노의학 시장을 조사했으며, 시장 정의와 개요, 시장 성장에 영향을 미치는 각종 영향요인 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별·주요 국가별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

영문목차

Global Nanomedicine Market Research Report: Information by Modality (Treatments and Diagnostics), by Application (Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, and Implants), and by Indication (Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Orthopedic Diseases, Neurological Diseases, Urological Diseases, Ophthalmological Diseases, Immunological Diseases, and Others), by Molecule Type (Nanoparticles [Albumin Particles, Inorganic Nanoparticles, Lipid Nanoparticle, Liposomes, and Others], Nanoshells, Nanotubes, and Nanodevices), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Market Overview

In 2023, the nanomedicine market was estimated at USD 252.97 billion. The Nanomedicine Market is expected to expand from USD 273.79 billion in 2024 to USD 819.84 billion by 2032, with a compound yearly growth rate (CAGR) of 12.48% over the forecast period (2024-2032).

The global market is being driven by increasing occurrences of various ailments around the world, as well as agreements related to nanomedicine product development.

Market Segment insights

The Nanomedicine Market is divided into two segments: treatments and diagnostics.

The Nanomedicine Market is divided into five applications: drug delivery, diagnostic imaging, vaccinations, regenerative medicine, and implants.

The Nanomedicine Market has been classified by indication: oncological illnesses, infectious diseases, cardiovascular diseases, orthopedic disorders, neurological diseases, urological diseases, ophthalmological diseases, immunological diseases, and others.

The Nanomedicine Market is divided into four segments based on molecule type: nanoparticles, nanoshells, nanotubes, and nanodevices.

Regional insights

The market is segmented into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America held the biggest market share of more than 38.14% in 2023, owing to the rising prevalence of cancer cases and a strong research and development infrastructure. For example, in 2020, the United States reported 1,603,844 new cancer cases and 602,347 cancer deaths. There were 403 new cancer cases reported per 100,000 people, with 144 people dying from cancer.

The market for nanomedicine in Europe is rapidly developing as a result of advances in nanotechnology and its potential to improve healthcare. This market covers the development and application of nanoscale materials and technologies for monitoring, therapy, and diagnostics. The market is developing as a result of increased demand for tailored therapy and the rising prevalence of chronic diseases. Europe is at the forefront of nanomedicine breakthroughs, thanks to its high R&D spending and excellent healthcare infrastructure. Targeted drug delivery systems, better cancer therapies, and nanoscale imaging tools are key areas of focus.

The Asia-Pacific nanomedicine industry is rapidly developing, reflecting the region's increased interest and investment in cutting-edge healthcare technology. The market is predicted to grow fast due to several factors, including increased healthcare demand, rising chronic illness prevalence, and significant advances in nanotechnology research.

Major Players

Sanofi (France), Johnson & Johnson Services, Inc. (US), Parvus Therapeutics Inc. (US), Nanobiotix (France), Ascendia Pharmaceuticals (US), Bristol-Myers Squibb Company (US), Jazz Pharmaceuticals (Ireland), Cytimmune Sciences, Inc. (US), Nanospectra Biosciences (US), and Pfizer, Inc. (US) are among the key companies in the nanomedicine market.

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF VARIOUS DISEASES ACROSS THE GLOBE
- 4.2.2 AGREEMENTS ASSOCIATED WITH NANOMEDICINE PRODUCTS DEVELOPMENTS
4.3 RESTRAINTS
- 4.3.1 HIGH MANUFACTURING COST OF NANOMEDICINE
4.4 OPPORTUNITY
- 4.4.1 INCREASING NUMBER OF PIPELINE PRODUCTS

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL NANOMEDICINE MARKET

6 GLOBAL NANOMEDICINE MARKET, BY MODALITY

6.1 OVERVIEW
6.2 TREATMENTS
6.3 DIAGNOSTICS

7 GLOBAL NANOMEDICINE MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 DRUG DELIVERY
7.3 DIAGNOSTIC IMAGING
7.4 VACCINES
7.5 REGENERATIVE MEDICINE
7.6 IMPLANTS

8 GLOBAL NANOMEDICINE MARKET, BY INDICATION

8.1 OVERVIEW
8.2 ONCOLOGICAL DISEASES
8.3 INFECTIOUS DISEASES
8.4 CARDIOVASCULAR DISEASES
8.5 ORTHOPEDIC DISEASES
8.6 NEUROLOGICAL DISEASES
8.7 UROLOGICAL DISEASES
8.8 OPHTHALMOLOGICAL DISEASES
8.9 IMMUNOLOGICAL DISEASES
8.10 OTHERS

9 GLOBAL NANOMEDICINE MARKET, BY MOLECULE TYPE

9.1 OVERVIEW
9.2 NANOPARTICLES
9.3 NANOSHELLS
9.4 NANOTUBES
9.5 NANODEVICES
- 9.5.1 ALBUMIN PARTICLES
- 9.5.2 INORGANIC NANOPARTICLES
- 9.5.3 LIPID NANOPARTICLE
- 9.5.4 LIPOSOMES
- 9.5.5 OTHERS

10 GLOBAL NANOMEDICINE MARKET, BY REGION

10.1 OVERVIEW
10.2 NORTH AMERICA
- 10.2.1 US
- 10.2.2 CANADA
10.3 EUROPE
- 10.3.1 GERMANY
- 10.3.2 FRANCE
- 10.3.3 UK
- 10.3.4 ITALY
- 10.3.5 SPAIN
- 10.3.6 REST OF EUROPE
10.4 ASIA-PACIFIC
- 10.4.1 CHINA
- 10.4.2 INDIA
- 10.4.3 JAPAN
- 10.4.4 SOUTH KOREA
- 10.4.5 AUSTRALIA
- 10.4.6 REST OF ASIA-PACIFIC
10.5 REST OF THE WORLD
- 10.5.1 MIDDLE EAST
- 10.5.2 AFRICA
- 10.5.3 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 MARKET SHARE ANALYSIS,
11.3 COMPETITOR DASHBOARD
11.4 PUBLIC PLAYERS STOCK SUMMARY
11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 11.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
- 11.6.2 PARTNERSHIP/AGREEMENT/COLLABORATION

12 COMPANY PROFILES

12.1 SANOFI
- 12.1.1 COMPANY OVERVIEW
- 12.1.2 FINANCIAL OVERVIEW
- 12.1.3 PRODUCTS OFFERED
- 12.1.4 KEY DEVELOPMENTS
- 12.1.5 SWOT ANALYSIS
- 12.1.6 KEY STRATEGIES
12.2 JOHNSON & JOHNSON SERVICES, INC.
- 12.2.1 COMPANY OVERVIEW
- 12.2.2 FINANCIAL OVERVIEW
- 12.2.3 PRODUCTS OFFERED
- 12.2.4 KEY DEVELOPMENTS
- 12.2.5 SWOT ANALYSIS
- 12.2.6 KEY STRATEGY
12.3 PARVUS THERAPEUTICS INC.
- 12.3.1 COMPANY OVERVIEW
- 12.3.2 FINANCIAL OVERVIEW
- 12.3.3 PRODUCTS OFFERED
- 12.3.4 KEY DEVELOPMENTS
- 12.3.5 KEY STRATEGIES
12.4 NANOBIOTIX
- 12.4.1 COMPANY OVERVIEW
- 12.4.2 FINANCIAL OVERVIEW
- 12.4.3 PRODUCTS OFFERED
- 12.4.4 KEY DEVELOPMENTS
- 12.4.5 KEY STRATEGY
12.5 ASCENDIA PHARMACEUTICAL
- 12.5.1 COMPANY OVERVIEW
- 12.5.2 FINANCIAL OVERVIEW
- 12.5.3 PRODUCTS OFFERED
- 12.5.4 KEY DEVELOPMENTS
- 12.5.5 KEY STRATEGY
12.6 BRISTOL-MYERS SQUIBB COMPANY
- 12.6.1 COMPANY OVERVIEW
- 12.6.2 FINANCIAL OVERVIEW
- 12.6.3 PRODUCTS OFFERED
- 12.6.4 KEY DEVELOPMENTS
- 12.6.5 SWOT ANALYSIS
- 12.6.6 KEY STRATEGIES
12.7 JAZZ PHARMACEUTICALS
- 12.7.1 COMPANY OVERVIEW
- 12.7.2 FINANCIAL OVERVIEW
- 12.7.3 PRODUCTS OFFERED
- 12.7.4 KEY DEVELOPMENTS
- 12.7.5 SWOT ANALYSIS
- 12.7.6 KEY STRATEGIES
12.8 CYTIMMUNE SCIENCES, INC.
- 12.8.1 COMPANY OVERVIEW
- 12.8.2 FINANCIAL OVERVIEW
- 12.8.3 PRODUCTS OFFERED
- 12.8.4 KEY DEVELOPMENTS
- 12.8.5 KEY STRATEGIES
12.9 NANOSPECTRA BIOSCIENCES
- 12.9.1 COMPANY OVERVIEW
- 12.9.2 FINANCIAL OVERVIEW
- 12.9.3 PRODUCTS OFFERED
- 12.9.4 KEY DEVELOPMENTS
- 12.9.5 KEY STRATEGIES
12.10 PFIZER INC
- 12.10.1 COMPANY OVERVIEW
- 12.10.2 FINANCIAL OVERVIEW
- 12.10.3 PRODUCTS OFFERED
- 12.10.4 KEY DEVELOPMENTS
- 12.10.5 SWOT ANALYSIS
- 12.10.6 KEY STRATEGIES

한글목차

목차

제1장 주요 요약

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

제5장 시장 요인 분석

제6장 세계의 나노의학 시장 : 모달리티별

제7장 세계의 나노의학 시장 : 용도별

제8장 세계의 나노의학 시장 : 적응증별

제9장 세계의 나노의학 시장 : 분자 유형별

제10장 세계의 나노의학 시장 : 지역별

제11장 경쟁 구도

제12장 기업 개요

제13장 데이터 인용